Natera, which sells non-invasive prenatal disease screening tests, raised $180 million by offering 10.0 million shares at $18, the high end of the range of $17 to $18. Natera previously filed to raise $100 million by offering 6.3 million shares at $15-$17. Natera plans to list on the NASDAQ under the symbol NTRA. Natera initially filed confidentially on 5/14/2014. Morgan Stanley, Cowen & Company and Piper Jaffray acted as lead managers on the deal.
